Medicinova (MNOV) Announces Acceptance of MN-166 ALS Abstract for Presentation at Upcoming ALS/MND Symposium
Tweet Send to a Friend
MediciNova, Inc. (Nasdaq: MNOV) announced that an abstract regarding MediciNova’s ongoing clinical trial of MN-166 (ibudilast) in ALS has been ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
